Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Gilead Sciences, Inc.NASDAQ: GILD

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses turns positive

Q2 FY2026 other income / expenses was $140M, compared with -$45M a year earlier. Trailing-twelve-month other income / expenses was -$462M.

Context

  • Other income / expenses amounted to 6.5% of revenue in FY2025, up 3.1 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $140M or moves back toward the trailing-twelve-month quarterly average of -$115.5M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$140M+2433.3% QoQ
Last fiscal yearDec 2025
-$1.91B-96.0% YoY
LTMJun 2026
-$462M+45.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+411.1%——
1 year-96.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(1.91B) USD
Year-over-year change
-96.0%

Other Income / Expenses vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +45.6% is the highest of 10, against a peer median of -93.0%.
  • Other income / expenses amounts to 1.5% of revenue for GILD, versus a peer median of 7.5%.
GILD Competitors
Other Income / Expenses for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GILDGilead Sciences, Inc.LTM Jun 2026-$462M USD+45.6%—1.5%
GSKGSK plcLTM Jun 2026-£969M GBP-93.0%—2.9%
AZNAstraZeneca PLCLTM Sep 2026-$1.46B USD-7.3%—2.4%
NVSNovartis AGLTM Jun 2026-$1.47B USD-36.4%—2.6%
SNYSanofiLTM Jun 2026-€2.04B EUR-845.8%—4.2%
MRKMerck & Co., Inc.LTM Jun 2026-$5.11B USD-128.1%—7.7%
LLYEli Lilly and CompanyLTM Jun 2026-$6.01B USD-7.8%—7.5%
JNJJohnson & JohnsonLTM Sep 2026-$7.79B USD-204.5%—7.8%
ABBVAbbVie Inc.LTM Sep 2026-$10.64B USD-44.2%—16.1%
PFEPfizer Inc.LTM Jun 2026-$12.81B USD-109.5%—20.1%
Peer median (excluding GILD) —-93.0%—7.5%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.